Trials / Completed
CompletedNCT03303170
Non-Significant Risk Study of Sebacia Microparticles in the Treatment of Facial Acne Vulgaris
A Prospective, Multicenter, Randomized, Controlled, Evaluator-Blinded Study of the Safety and Effectiveness of Sebacia Microparticles as an Accessory to 1064 nm Nd:Yag Laser in the Treatment of Facial Inflammatory Acne Vulgaris
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 168 (actual)
- Sponsor
- Sebacia, Inc. · Industry
- Sex
- All
- Age
- 12 Years – 45 Years
- Healthy volunteers
- Not accepted
Summary
Prospective, randomized, controlled, parallel group clinical study with blinded assessment evaluating Sebacia Microparticles (SM) with Nd:Yag laser in facial inflammatory acne vulgaris
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | Sebacia Microparticles | Topical microparticle suspension |
| DEVICE | Nd:Yag Laser | Laser delivering 1064 nm wavelength light |
Timeline
- Start date
- 2017-09-25
- Primary completion
- 2018-04-10
- Completion
- 2018-04-10
- First posted
- 2017-10-05
- Last updated
- 2019-10-14
Locations
11 sites across 1 country: United States
Regulatory
- FDA-regulated device study
Source: ClinicalTrials.gov record NCT03303170. Inclusion in this directory is not an endorsement.